Literature DB >> 20203323

Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative.

Swapnil N Rajpathak1, Tao Wang, Sylvia Wassertheil-Smoller, Howard D Strickler, Robert C Kaplan, Aileen P McGinn, Rachel P Wildman, Daniel Rosenbaum, Thomas E Rohan, Philipp E Scherer, Mary Cushman, Gloria Y F Ho.   

Abstract

BACKGROUND AND
PURPOSE: Hepatocyte growth factor (HGF) is a potent angiogenic factor and may play a role in the development and progression of atherosclerotic lesions, the underlying mechanism of cardiovascular disease. However, there have been no prospective studies examining the relationship between HGF levels and risk of stroke.
METHODS: We conducted a nested case-control study (972 incident stroke cases and 1:1 age-matched and race-matched controls) to prospectively evaluate the association between plasma HGF and risk of ischemic stroke within the Women's Health Initiative Observational Study, a cohort of postmenopausal women aged 50 to 79 years.
RESULTS: Baseline HGF levels were correlated positively with body mass index, systolic blood pressure, low-density lipoprotein cholesterol, insulin resistance, and inflammatory markers, such as C-reactive protein, and inversely with high-density lipoprotein cholesterol (all P<0.05). Baseline HGF levels were higher among cases than controls (geometric means, 601.8 vs 523.2 pg/mL; P=0.003). Furthermore, the risk of incident ischemic stroke was significantly greater among women in the highest vs lowest quartile of plasma HGF levels (OR, 1.46; 95% CI, 1.12-1.91; P(trend)=0.003) in a conditional logistic regression model that adjusted for body mass index. These results were only slightly attenuated after further adjustment for additional stroke risk factors (OR, 1.39; 95% CI, 1.04-1.85; P(trend)=0.023).
CONCLUSIONS: Circulating levels of HGF are associated with an increased risk of incident ischemic stroke, independent of obesity and other risk factors for cardiovascular disease, among postmenopausal women aged 50 to 79 years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20203323      PMCID: PMC3903044          DOI: 10.1161/STROKEAHA.109.567719

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  34 in total

1.  The Women's Health Initiative recruitment methods and results.

Authors:  Jennifer Hays; Julie R Hunt; F Allan Hubbell; Garnet L Anderson; Marian Limacher; Catherine Allen; Jacques E Rossouw
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

2.  Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis.

Authors:  Karen S Moulton; Khashayar Vakili; David Zurakowski; Mohsin Soliman; Catherine Butterfield; Erik Sylvin; Kin-Ming Lo; Stephen Gillies; Kashi Javaherian; Judah Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

3.  Obesity is associated with increased levels of circulating hepatocyte growth factor.

Authors:  Jalees Rehman; Robert V Considine; Jason E Bovenkerk; Jingling Li; Catharine A Slavens; Rose Marie Jones; Keith L March
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

4.  Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction.

Authors:  Akira Matsumori; Hajime Takano; Jun-ei Obata; Satoshi Takeda; Naohiko Tsuyuguchi; Koh Ono; Masaharu Okada; Tadashi Miyamoto; Tomokazu Ohnishi; Yasushi Daikuhara; Shigetake Sasayama
Journal:  Circ J       Date:  2002-02       Impact factor: 2.993

5.  Hepatocyte growth factor-stimulated invasiveness of monocytes.

Authors:  M Beilmann; G F Vande Woude; H P Dienes; P Schirmacher
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

6.  Plasma hepatocyte growth factor and the relationship between risk factors and carotid atherosclerosis.

Authors:  Yoshikuni Yamamoto; Katsuhiko Kohara; Yasuharu Tabara; Michiya Igase; Jun Nakura; Tetsuro Miki
Journal:  Hypertens Res       Date:  2002-09       Impact factor: 3.872

Review 7.  Hepatocyte growth factor as cardiovascular hormone: role of HGF in the pathogenesis of cardiovascular disease.

Authors:  Ryuichi Morishita; Motokuni Aoki; Yoshikage Yo; Toshio Ogihara
Journal:  Endocr J       Date:  2002-06       Impact factor: 2.349

8.  Significance of serum circulating hepatocyte growth factor in the development of carotid atherosclerosis.

Authors:  Ryuichi Kawamoto; Yuichiro Oka; Osamu Yoshida; Yaemi Takagi
Journal:  J Atheroscler Thromb       Date:  2003       Impact factor: 4.928

9.  Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function.

Authors:  Wolfgang Lieb; Radwan Safa; Emelia J Benjamin; Vanessa Xanthakis; Xiaoyan Yin; Lisa M Sullivan; Martin G Larson; Holly M Smith; Joseph A Vita; Gary F Mitchell; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Eur Heart J       Date:  2009-02-17       Impact factor: 29.983

10.  Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques.

Authors:  Harry Ma; Tina M Calderon; John T Fallon; Joan W Berman
Journal:  Atherosclerosis       Date:  2002-09       Impact factor: 5.162

View more
  19 in total

Review 1.  Emerging risk factors in women.

Authors:  Kathryn M Rexrode
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

2.  Interleukin-6, interleukin-6 receptor gene variant, small-vessel disease and incident dementia.

Authors:  K Miwa; S Okazaki; M Sakaguchi; H Mochizuki; K Kitagawa
Journal:  Eur J Neurol       Date:  2016-01-03       Impact factor: 6.089

3.  Elevated Levels of Adhesion Proteins Are Associated With Low Ankle-Brachial Index.

Authors:  Cecilia Berardi; Christine L Wassel; Paul A Decker; Nicholas B Larson; Phillip S Kirsch; Mariza de Andrade; Michael Y Tsai; James S Pankow; Michele M Sale; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Mary M McDermott; Michael H Criqui; Michael A Allison; Suzette J Bielinski
Journal:  Angiology       Date:  2016-07-20       Impact factor: 3.619

4.  Antiangiogenesis and medical therapy failure in intracranial atherosclerosis.

Authors:  Nestor R Gonzalez; Raymond Liou; Florian Kurth; Hao Jiang; Jeffrey Saver
Journal:  Angiogenesis       Date:  2017-10-09       Impact factor: 9.596

5.  Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke.

Authors:  Zhengbao Zhu; Tan Xu; Daoxia Guo; Xinfeng Huangfu; Chongke Zhong; Jingyuan Yang; Aili Wang; Chung-Shiuan Chen; Yanbo Peng; Tian Xu; Jinchao Wang; Yingxian Sun; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Jing Chen; Yonghong Zhang; Jiang He
Journal:  Stroke       Date:  2018-01-10       Impact factor: 7.914

6.  Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Michael P Bancks; Suzette J Bielinski; Paul A Decker; Naomi Q Hanson; Nicholas B Larson; Hugues Sicotte; Christina L Wassel; James S Pankow
Journal:  Metabolism       Date:  2015-10-21       Impact factor: 8.694

7.  Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the Women's Health Initiative.

Authors:  Swapnil N Rajpathak; Robert C Kaplan; Sylvia Wassertheil-Smoller; Mary Cushman; Thomas E Rohan; Aileen P McGinn; Tao Wang; Howard D Strickler; Philipp E Scherer; Rachel Mackey; David Curb; Gloria Y F Ho
Journal:  Stroke       Date:  2011-05-05       Impact factor: 7.914

8.  Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults.

Authors:  Mekala R Raman; Jayandra J Himali; Sarah C Conner; Charles DeCarli; Ramachandran S Vasan; Alexa S Beiser; Sudha Seshadri; Pauline Maillard; Claudia L Satizabal
Journal:  Stroke       Date:  2018-09       Impact factor: 7.914

9.  Hepatocyte growth factor and clinical diabetes in postmenopausal women.

Authors:  Swapnil N Rajpathak; Sylvia Wassertheil-Smoller; Jill Crandall; Simin Liu; Gloria Y F Ho
Journal:  Diabetes Care       Date:  2010-06-02       Impact factor: 19.112

Review 10.  Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Taku Tsunoda; Yuzo Yano; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Diabetes       Date:  2014-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.